Antibodies
13 August 2008
Morphotek(R), Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate Cancer12 August 2008
MedImmune Initiates First Phase 2 Trial in Lupus Patients With its Antibody Targeting Interferon-alpha11 August 2008
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer11 August 2008
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist6 August 2008
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial30 July 2008
FDA Advisory Committee recommends approval of Actemra for the treatment of rheumatoid arthritis28 July 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial23 July 2008
Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics23 July 2008
MorphoSys Licenses RapMAT Technology to Astellas22 July 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis21 July 2008
Goodwin Biotechnology’s Manufactured Melanin-Binding Antibody Used in Successful Melanoma TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports